Skip Navigation


Annals of Oncology Advance Access originally published online on May 4, 2007
Annals of Oncology 2007 18(7):1185-1189; doi:10.1093/annonc/mdm124
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
18/7/1185    most recent
mdm124v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in Ann Oncol
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (6)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Meyerhardt, J.
Right arrow Articles by Ryan, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Meyerhardt, J.
Right arrow Articles by Ryan, D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2007 European Society for Medical Oncology

gastrointestinal tumors

Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with metastastic colorectal cancer

JA Meyerhardt1,*, K Stuart2,{dagger}, CS Fuchs1, AX Zhu3, CC Earle1, P Bhargava1, L Blaszkowsky3, P Enzinger1, RJ Mayer1, S Battu1, C Lawrence1 and DP Ryan3

1 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
2 Division of Medical Oncology, Beth-Israel Deaconess Medical Center, Boston, MA
3 Division of Medical Oncology, Massachusetts General Hospital, Boston, MA, USA

* Correspondence to: Dr J. A. Meyerhardt, Dana-Farber Cancer Institute, Boston, MA 02115, USA. Tel: +1 617-632-6855; Fax: +1 617-632-5370; E-mail: jmeyerhardt{at}partners.org

Background: Targeting the epidermal growth factor receptor and angiogenesis have proven useful strategies against metastatic colorectal cancer. The benefit of combining inhibitors of both pathways is unknown.

Patients and methods: Patients with previously untreated metastatic colorectal cancer were enrolled in a phase II trial of infusional 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX), bevacizumab and erlotinib. The primary end point was progression-free survival.

Results: Thirty-five patients were enrolled and all came off trial for reasons other than progression; 18 (51%) had protocol-defined adverse events requiring removal, nine (26%) withdrew consent due to toxicity, six pursued surgery or localized therapies and two requested a treatment holiday. Principal toxic effects included rash, neuropathy and diarrhea. Seven patients came off trial before first restaging. By intention-to-treat analysis, one patient had a confirmed complete response, 10 had confirmed partial responses and one had an unconfirmed partial response (response rate = 34%). One patient had progressive disease at time of withdrawal from the trial, thus progression-free survival could not be calculated.

Conclusion: The combination of FOLFOX, bevacizumab and erlotinib led to higher than expected early withdrawal due to toxicity, limiting conclusions regarding efficacy. These findings raise concern regarding the tolerability of adding more agents to already complex combination regimens for metastatic colorectal cancer.

Key words: bevacizumab, colorectal cancer, erlotinib, FOLFOX

{dagger} Present address: Lahey Clinic, Burlington, MA, USA.

Received for publication March 8, 2007. Accepted for publication March 13, 2007.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in Ann Oncol:

In this issue

Ann Oncol 2007 18: 1127. [Extract] [Full Text]  



This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
G. Folprecht, J. Tabernero, C.-H. Kohne, C. Zacharchuk, L. Paz-Ares, F. Rojo, S. Quinn, E. Casado, R. Salazar, R. Abbas, et al.
Phase I Pharmacokinetic/Pharmacodynamic Study of EKB-569, an Irreversible Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Combination with Irinotecan, 5-Fluorouracil, and Leucovorin (FOLFIRI) in First-Line Treatment of Patients with Metastatic Colorectal Cancer
Clin. Cancer Res., January 1, 2008; 14(1): 215 - 223.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.